Immuneering (IMRX) Expected to Announce Quarterly Earnings on Friday

Immuneering (NASDAQ:IMRX) is projected to announce its earnings results before the market opens on Friday, March 7th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.

Immuneering Stock Performance

Shares of IMRX stock opened at $1.50 on Thursday. The stock’s 50-day moving average is $1.94 and its two-hundred day moving average is $1.95. The firm has a market cap of $46.58 million, a price-to-earnings ratio of -0.76 and a beta of -0.36. Immuneering has a 1 year low of $1.00 and a 1 year high of $6.78.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of Immuneering in a report on Thursday, February 6th. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Finally, Chardan Capital reissued a “buy” rating and set a $13.00 price target on shares of Immuneering in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.00.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.